Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 3Recurrence 2Rectal Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Colonic Neoplasms 1Alopecia 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Immunoconjugates × Clear all
NCT07052760 2026-04-29

Imaging of Solid Tumors Using DLL3 SPECT

University of California, San Francisco

Phase EARLY_PHASE1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡